Furanyl-rhodanines are unattractive drug candidates for development as inhibitors of bacterial RNA polymerase - PubMed (original) (raw)

Furanyl-rhodanines are unattractive drug candidates for development as inhibitors of bacterial RNA polymerase

Katherine R Mariner et al. Antimicrob Agents Chemother. 2010 Oct.

Abstract

Previous studies suggest that furanyl-rhodanines might specifically inhibit bacterial RNA polymerase (RNAP). We further explored three compounds from this class. Although they inhibited RNAP, each compound also inhibited malate dehydrogenase and chymotrypsin. Using biosensors responsive to inhibition of macromolecular synthesis and membrane damaging assays, we concluded that in bacteria, one compound inhibited DNA synthesis and another caused membrane damage. The third rhodanine lacked antibacterial activity. We consider furanyl-rhodanines to be unattractive RNAP inhibitor drug candidates.

PubMed Disclaimer

References

    1. Agarwal, A. K., A. P. Johnson, and C. W. G. Fishwick. 2008. Synthesis of de novo designed small-molecule inhibitors of bacterial RNA polymerase. Tetrahedron 64**:**10049-10054.
    1. Chopra, I. 2007. Bacterial RNA polymerase: a promising target for the discovery of new antimicrobial agents. Curr. Opin. Invest. Drugs 8**:**600-607. -PubMed
    1. Dixon, R., and I. Chopra. 1986. Leakage of periplasmic proteins from Escherichia coli mediated by the polymyxin analogue, polymyxin B nonapeptide. Antimicrob. Agents Chemother. 29**:**781-788. -PMC -PubMed
    1. Grant, E. B., D. Guiadeen, E. Z. Baum, B. D. Foleno, H. Jin, D. A. Montenegro, E. A. Nelson, K. Bush, and D. J. Hlasta. 2000. The synthesis and SAR of rhodanines as novel class C β-lactamase inhibitors. Bioorg. Med. Chem. Lett. 10**:**2179-2182. -PubMed
    1. Hobbs, J. K., K. Miller, A. J. O'Neill, and I. Chopra. 2008. Consequences of daptomycin-mediated membrane damage in Staphylococcus aureus. J. Antimicrob. Chemother. 62**:**1003-1008. -PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources